VIRACTA THERAPEUTICS INC

$2.15 0.00% ($0.00)

Get ready to invest

About VIRACTA THERAPEUTICS INC

Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a precision oncology company. The Company is focused on the development of new medicines targeting virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The Company is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.

Popular Stocks	Price	Change
Nu Holdings NU	$4.03 14.16%	14.16%
AMC AMC	$14.43 17.99%	17.99%
AMD AMD	$102.26 3.55%	3.55%
Nvidia NVDA	$188.11 5.38%	5.38%
Gap, Inc., The GPS	$11.6 4.32%	4.32%
Snap SNAP	$15.58 5.2%	5.2%
Ford F	$13.63 3.89%	3.89%
Apple AAPL	$149.64 4.08%	4.08%
Grab Holdings inc. GRAB	$2.41 3.88%	3.88%
NIO NIO	$16.57 3.37%	3.37%